However, traditional delivery methods, typically through injections, have posed challenges for some patients, spurring the development of more patient-friendly alternatives
They aid in capturing rare or delayed side effects
(Reuters) Known risk factors for NAION include: Diabetes High blood pressure High cholesterol Sleep apnea Smoking Medications that affect blood flow or circulation Because GLP-1 drugs influence metabolic function, blood sugar levels, and physiological processes that may affect circulation, plaintiffs in GLP-1 lawsuits allege that drug manufacturers knew or should have known about the potential risk of optic nerve damage and failed to adequately warn patients and healthcare providers
Long-Acting Amylin Agonist GUB014295 Gubra A/S (Hrsholm, Denmark), a biotech company specialized in pre-clinical contract research, initiated a phase 1 clinical trial (NCT06144684) to investigate the safety, tolerability and pharmacological properties of GUB014295 (GUBamy), a long-acting OW SC amylin agonist, in healthy volunteers [117]
